×
S&P 500   3,816.84 (-0.12%)
DOW   31,021.98 (+0.24%)
QQQ   283.06 (-0.17%)
AAPL   139.08 (+1.19%)
MSFT   260.20 (+1.45%)
META   162.34 (+1.03%)
GOOGL   2,219.25 (-0.93%)
AMZN   108.65 (+1.16%)
TSLA   679.45 (-2.66%)
NVDA   153.71 (-3.82%)
NIO   21.57 (-3.53%)
BABA   115.22 (-1.32%)
AMD   77.17 (-4.47%)
MU   55.64 (-3.84%)
CGC   3.51 (-2.77%)
T   20.96 (+1.70%)
GE   63.54 (-3.55%)
F   11.51 (-2.54%)
DIS   95.53 (-0.41%)
AMC   13.52 (+1.05%)
PFE   51.08 (+0.83%)
PYPL   71.02 (-1.11%)
NFLX   177.11 (-1.39%)
S&P 500   3,816.84 (-0.12%)
DOW   31,021.98 (+0.24%)
QQQ   283.06 (-0.17%)
AAPL   139.08 (+1.19%)
MSFT   260.20 (+1.45%)
META   162.34 (+1.03%)
GOOGL   2,219.25 (-0.93%)
AMZN   108.65 (+1.16%)
TSLA   679.45 (-2.66%)
NVDA   153.71 (-3.82%)
NIO   21.57 (-3.53%)
BABA   115.22 (-1.32%)
AMD   77.17 (-4.47%)
MU   55.64 (-3.84%)
CGC   3.51 (-2.77%)
T   20.96 (+1.70%)
GE   63.54 (-3.55%)
F   11.51 (-2.54%)
DIS   95.53 (-0.41%)
AMC   13.52 (+1.05%)
PFE   51.08 (+0.83%)
PYPL   71.02 (-1.11%)
NFLX   177.11 (-1.39%)
S&P 500   3,816.84 (-0.12%)
DOW   31,021.98 (+0.24%)
QQQ   283.06 (-0.17%)
AAPL   139.08 (+1.19%)
MSFT   260.20 (+1.45%)
META   162.34 (+1.03%)
GOOGL   2,219.25 (-0.93%)
AMZN   108.65 (+1.16%)
TSLA   679.45 (-2.66%)
NVDA   153.71 (-3.82%)
NIO   21.57 (-3.53%)
BABA   115.22 (-1.32%)
AMD   77.17 (-4.47%)
MU   55.64 (-3.84%)
CGC   3.51 (-2.77%)
T   20.96 (+1.70%)
GE   63.54 (-3.55%)
F   11.51 (-2.54%)
DIS   95.53 (-0.41%)
AMC   13.52 (+1.05%)
PFE   51.08 (+0.83%)
PYPL   71.02 (-1.11%)
NFLX   177.11 (-1.39%)
S&P 500   3,816.84 (-0.12%)
DOW   31,021.98 (+0.24%)
QQQ   283.06 (-0.17%)
AAPL   139.08 (+1.19%)
MSFT   260.20 (+1.45%)
META   162.34 (+1.03%)
GOOGL   2,219.25 (-0.93%)
AMZN   108.65 (+1.16%)
TSLA   679.45 (-2.66%)
NVDA   153.71 (-3.82%)
NIO   21.57 (-3.53%)
BABA   115.22 (-1.32%)
AMD   77.17 (-4.47%)
MU   55.64 (-3.84%)
CGC   3.51 (-2.77%)
T   20.96 (+1.70%)
GE   63.54 (-3.55%)
F   11.51 (-2.54%)
DIS   95.53 (-0.41%)
AMC   13.52 (+1.05%)
PFE   51.08 (+0.83%)
PYPL   71.02 (-1.11%)
NFLX   177.11 (-1.39%)
CVE:SVA

Sernova Stock Forecast, Price & News

C$1.57
+0.09 (+6.08%)
(As of 06/1/2022)
Add
Compare
Today's Range
C$1.46
C$1.57
50-Day Range
C$1.38
C$1.57
52-Week Range
C$1.16
C$2.22
Volume
121,355 shs
Average Volume
288,358 shs
Market Capitalization
C$432.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
30 days | 90 days | 365 days | Advanced Chart

Receive SVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sernova and its competitors with MarketBeat's FREE daily newsletter.

SVA Stock Forecast (MarketRank)

Overall MarketRank

1.19 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
Sernova logo

About Sernova (CVE:SVA)

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.

SVA Stock News Headlines

Sernova Corp. (SVA.TO)
IIROC Trading Halt - SVA
See More Headlines

Industry, Sector and Symbol

Industry
Diagnostics & Research
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
1,959
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$0.10 per share
Book Value
C$0.10 per share

Miscellaneous

Free Float
N/A
Market Cap
C$432.57 million
Optionable
Optionable
Beta
N/A














Sernova Frequently Asked Questions

Should I buy or sell Sernova stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sernova in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Sernova stock.
View analyst ratings for Sernova
or view top-rated stocks.

How has Sernova's stock price performed in 2022?

Sernova's stock was trading at C$1.82 at the beginning of 2022. Since then, SVA shares have decreased by 13.7% and is now trading at C$1.57.
View the best growth stocks for 2022 here
.

What other stocks do shareholders of Sernova own?

What is Sernova's stock symbol?

Sernova trades on the Canadian Venture Exchange (CVE) under the ticker symbol "SVA."

How do I buy shares of Sernova?

Shares of SVA and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Sernova's stock price today?

One share of SVA stock can currently be purchased for approximately C$1.57.

How much money does Sernova make?

Sernova (CVE:SVA) has a market capitalization of C$432.57 million.

How many employees does Sernova have?

Sernova employs 1,959 workers across the globe.

How can I contact Sernova?

Sernova's mailing address is 700 Collip Cir Suite 114, LONDON, ON N6G 4X8, Canada. The official website for Sernova is www.sernova.com. The company can be reached via phone at +1-519-8585184.

This page (CVE:SVA) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.